Novo Nordisk AS (NONOF)
105.00
+2.16
(+2.10%)
USD |
OTCM |
Nov 22, 16:00
Novo Nordisk Profit Margin (Quarterly): 38.28% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 38.28% |
June 30, 2024 | 29.46% |
March 31, 2024 | 38.88% |
December 31, 2023 | 33.35% |
September 30, 2023 | 38.27% |
June 30, 2023 | 35.78% |
March 31, 2023 | 37.13% |
December 31, 2022 | 28.26% |
September 30, 2022 | 31.61% |
June 30, 2022 | 32.27% |
March 31, 2022 | 33.81% |
December 31, 2021 | 28.41% |
September 30, 2021 | 34.02% |
June 30, 2021 | 36.69% |
March 31, 2021 | 37.34% |
December 31, 2020 | 28.99% |
September 30, 2020 | 33.30% |
June 30, 2020 | 35.41% |
March 31, 2020 | 35.12% |
December 31, 2019 | 26.89% |
September 30, 2019 | 33.67% |
June 30, 2019 | 31.94% |
March 31, 2019 | 35.66% |
December 31, 2018 | 28.58% |
September 30, 2018 | 32.55% |
Date | Value |
---|---|
June 30, 2018 | 37.74% |
March 31, 2018 | 39.92% |
December 31, 2017 | 29.48% |
September 30, 2017 | 36.71% |
June 30, 2017 | 34.75% |
March 31, 2017 | 35.70% |
December 31, 2016 | 29.42% |
September 30, 2016 | 35.60% |
June 30, 2016 | 36.30% |
March 31, 2016 | 34.75% |
December 31, 2015 | 28.60% |
September 30, 2015 | 31.29% |
June 30, 2015 | 30.83% |
March 31, 2015 | 39.19% |
December 31, 2014 | 26.56% |
September 30, 2014 | 29.21% |
June 30, 2014 | 32.34% |
March 31, 2014 | 31.75% |
December 31, 2013 | 27.90% |
September 30, 2013 | 31.28% |
June 30, 2013 | 31.50% |
March 31, 2013 | 29.94% |
December 31, 2012 | 27.45% |
September 30, 2012 | 28.56% |
June 30, 2012 | 27.46% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
26.89%
Minimum
Dec 2019
38.88%
Maximum
Mar 2024
33.66%
Average
33.91%
Median
Profit Margin (Quarterly) Benchmarks
Eli Lilly and Co | 8.48% |
Genmab AS | 22.85% |
Ascendis Pharma AS | -171.5% |
Galecto Inc | -- |
Profit Margin (Quarterly) Related Metrics
Return on Equity | 88.95% |
Return on Assets | 28.14% |
Return on Invested Capital | 65.63% |
Gross Profit Margin (Quarterly) | 84.14% |
Operating Margin (Quarterly) | 47.43% |
Return on Net Operating Assets | 31.93% |